EUVIMEDEUVIMED entdecken
Crossref

The L‐arginine‐NO‐cGMP pathway mediates the locomotor activity alterations during the expression of sensitization to mephedrone in mice

Gabriela Bielecka-Papierz iD, Ewa Poleszak, Joanna Listos, Bernadeta Szewczyk, Aleksandra Szopa iD, Jolanta Orzelska-Górka, Justyna Turek, Dorota Bederska-Łojewska, Małgorzata Jakóbczuk, Jarosław Szponar, Sylwia Talarek, Anna Serefko

Clinical and Experimental Pharmacology and Physiology · 2023

DOI: 10.1111/1440-1681.13779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2023. Verfasst von Gabriela Bielecka-Papierz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, Lublin, Poland. Hauptthemen laut MEDLINE: Methylene Blue, Nitric Oxide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mephedrone is a representative of synthetic cathinones that is known from its rewarding and psychostimulant effects. It exerts behavioural sensitization after repeated and then interrupted administration. In our study, we investigated a role of the L‐arginine‐NO‐cGMP‐dependent signalling in the expression of sensitization to hyperlocomotion evoked by mephedrone. The study was carried out in male albino Swiss mice. The tested mice received mephedrone (2.5 mg/kg) for 5 consecutive days and on the 20th day of the experiment (the ‘challenge’ day) animals received both mephedrone (2.5 mg/kg) and a given substance that affects the L‐arginine‐NO‐cGMP signalling, that is, L‐arginine hydrochloride (125 or 250 mg/kg), 7‐nitroindazole (10 or 20 mg/kg), L‐NAME (25 or 50 mg/kg) or methylene blue (5 or 10 mg/kg). We observed that 7‐nitroindazole, L‐NAME and methylene blue inhibited the expression of sensitization to the mephedrone‐induced hyperlocomotion. Moreover, we demonstrated that the mephedrone‐induced sensitization is accompanied by lowered levels of D 1 receptors and NR2B subunits in the hippocampus, whereas a concurrent administration of L‐arginine hydrochloride, 7‐nitroindazole and L‐NAME with the mephedrone challenge dose reversed these effects. Methylene blue only reversed the mephedrone‐induced effects on hippocampal levels of the NR2B subunit. Our study confirms that the L‐arginine‐NO‐cGMP pathway contributes to mechanisms underlying the expression of sensitization to the mephedrone‐evoked hyperlocomotion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methylene BlueNitric OxideMiceMaleAnimalsNG-Nitroarginine Methyl EsterArginineLocomotionCyclic GMPMethamphetamine

Stichwörter der Autor:innen

D1 receptorsL-arginine-NO-cGMP-dependent pathwayNR2B receptorsmephedronesensitization

Substanzen

NG-Nitroarginine Methyl EsterMethylene BlueNitric OxideArginineCyclic GMPmephedroneMethamphetamine

Autor:innen und Institutionen

  • Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, Lublin, Poland.
  • Laboratory of Preclinical Testing, Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, Lublin, Poland.
  • Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Lublin, Poland.
  • Department of Neurobiology, Polish Academy of Sciences, Maj Institute of Pharmacology, Kraków, Poland.
  • Department of Clinical Pharmacy and Pharmaceutical Care, Medical University of Lublin, Lublin, Poland.
  • Toxicology Clinic, Clinical Department of Toxicology and Cardiology, Medical University of Lublin, Stefan Wyszyński Regional Specialist Hospital, Lublin, Poland.

ORCID-Profile: Gabriela Bielecka-Papierz, Aleksandra Szopa

Zitieren

APA

Bielecka-Papierz, G., Poleszak, E., Listos, J., Szewczyk, B., Szopa, A., Orzelska-Górka, J., Turek, J., Bederska-Łojewska, D., Jakóbczuk, M., Szponar, J., Talarek, S., & Serefko, A. (2023). The L‐arginine‐NO‐cGMP pathway mediates the locomotor activity alterations during the expression of sensitization to mephedrone in mice. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.13779

Vancouver

Bielecka-Papierz G, Poleszak E, Listos J, Szewczyk B, Szopa A, Orzelska-Górka J, et al. The L‐arginine‐NO‐cGMP pathway mediates the locomotor activity alterations during the expression of sensitization to mephedrone in mice. Clinical and Experimental Pharmacology and Physiology. 2023. doi:10.1111/1440-1681.13779

BibTeX
@article{BieleckaPapierz2023,
  author = {Bielecka-Papierz, Gabriela and Poleszak, Ewa and Listos, Joanna and Szewczyk, Bernadeta and Szopa, Aleksandra and Orzelska-Górka, Jolanta and Turek, Justyna and Bederska-Łojewska, Dorota and Jakóbczuk, Małgorzata and Szponar, Jarosław and Talarek, Sylwia and Serefko, Anna},
  title = {The L‐arginine‐NO‐cGMP pathway mediates the locomotor activity alterations during the expression of sensitization to mephedrone in mice},
  journal = {Clinical and Experimental Pharmacology and Physiology},
  year = {2023},
  doi = {10.1111/1440-1681.13779}
}
Kostenlos starten →